Rxivist logo

Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines

By Baoying Huang, Lianpan Dai, Hui Wang, Zhongyu Hu, Wenjie Tan, George F. Gao, Xiaoming Yang

Posted 02 Feb 2021
bioRxiv DOI: 10.1101/2021.02.01.429069

Recently, the emerged and rapidly spreading SARS-CoV-2 variant of concern (VOC) 501Y.V2 with 10 amino acids in spike protein were found to escape host immunity induced by infection or vaccination. Global concerns have been raised for its potential to affect vaccine efficacy. Here, we evaluated the neutralization activities of two vaccines developed in China against 501Y.V2. One is licensed inactivated vaccine BBIBP-CorV and the other one is recombinant dimeric receptor-binding domain (RBD) vaccine ZF2001. Encouragingly, both vaccines largely preserved neutralizing titres, with slightly reduction, against 501Y.V2 authentic virus compare to their titres against both original SARS-CoV-2 and the currently circulating D614G virus. These data indicated that 501Y.V2 variant will not escape the immunity induced by vaccines targeting whole virus or RBD.

Download data

  • Downloaded 17,375 times
  • Download rankings, all-time:
    • Site-wide: 467
    • In microbiology: 53
  • Year to date:
    • Site-wide: 103
  • Since beginning of last month:
    • Site-wide: 25,297

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide